US2018237839A1PendingUtilityA1

Selective oxidation of 5-methylcytosine by tet-family proteins

Assignee: CHILDRENS MEDICAL CT CORPPriority: Sep 26, 2008Filed: Apr 13, 2018Published: Aug 23, 2018
Est. expirySep 26, 2028(~2.2 yrs left)· nominal 20-yr term from priority
G01N 2500/00C12Q 1/6869G01N 33/5308C12Q 2522/10C12Q 1/6806C12Q 1/6827C12Q 1/26G01N 33/5011C12Q 2600/154C12N 9/0071C12Q 2521/531C12Q 2537/164C12N 2501/71C12N 2501/70C12N 2501/724C12N 9/1007
78
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.

Claims

exact text as granted — not AI-modified
We claim: 
     
         1 . A kit comprising purified β-glucosyltransferase in a container and a labeled uridine diphosphoglucose in a container. 
     
     
         2 . The kit of  claim 1 , further comprising a buffer. 
     
     
         3 . The kit of  claim 1 , wherein the labeled uridine diphosphoglucose comprises a radiolabel. 
     
     
         4 . The kit of  claim 3 , wherein the radiolabel comprises  14 C or  3 H.

Join the waitlist — get patent alerts

Track US2018237839A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.